Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
PRNewswire - October 27, 2004
Stephen Sham, Chairman and CEO of MedMira said, "Over the past few years, MedMira has focused substantial efforts into gaining regulatory approval and opening the market channels in China for our rapid HIV test." Sham continued, "Not only have we succeeded in establishing an intricate sales network, but our MiraWell(TM) Rapid HIV Test is becoming a well-known diagnostic tool in China's battle against HIV/AIDS. We are extremely pleased to collaborate with these distinguished agencies by providing the highest quality tests which will make a difference in the front line of preventing HIV transmission."
The China-FPSA donation was made during a ceremony at the Great Hall of the People in Beijing, an honor of great magnitude for a foreign company. Among the distinguished attendees at the celebration was the former Minister of Health of China, Dr. Xinzhong Qian, who is currently the Honorary President of the China-FPSA. During the ceremony, the honorable former Minister of Health spoke of the MiraWell(TM) Rapid HIV Test as, "...the needed fire on a cold winter's night", in reference to the product's high quality, accuracy and 3-minute test results. The China-FPSA plans to dispatch MedMira's rapid HIV tests to the areas that will most benefit the Chinese population.
The ceremony was also attended by government officials, key representatives from the Centers of Disease Control (CDC), UNAIDS representatives, non-government AIDS healthcare organizations (NGOs), and prominent medical professionals.
The Department of Health for the municipality of Chongqing serves a population of approximately 31 million, and will use the donated tests to introduce MedMira's unique technology platform to small clinics, blood collection centers and hospital laboratories throughout the region. The donation was accepted by CDC representatives from the city of Chongqing. China has been reported to be battling one of the most rapidly increasing HIV infection rates in the world (rising 30% yearly since 1998). It is currently estimated that 1 million Chinese are HIV- infected and that, without intervention, China can anticipate up to 10 million HIV-infected and 260,000 orphans by 2010.
About MedMira
MedMira is a leading global manufacturer and marketer of in vitro rapid diagnostic tests for the clinical laboratory market. MedMira's tests issue reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV, hepatitis B and hepatitis C. The United States Food and Drug Administration (FDA) and the State Food and Drug Administration (SFDA), in the People's Republic of China, have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira has the only rapid diagnostic device to receive these two prominent government approvals. For more details visit MedMira's website at http://www.medmira.com.
MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing are located in Halifax, Nova Scotia, Canada.
This news release contains forward-looking statements, which involves risks and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
041027
PR041039
Copyright © 2004 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .